Robert Whittenbaugh

Array ( [id] => 19599544 [patent_doc_number] => 20240390424 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-28 [patent_title] => CYTOKINE ASSOCIATED TUMOR INFILTRATING LYMPHOCYTES COMPOSITIONS AND METHODS [patent_app_type] => utility [patent_app_number] => 18/781928 [patent_app_country] => US [patent_app_date] => 2024-07-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 292353 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18781928 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19432583 [patent_doc_number] => 20240301081 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-12 [patent_title] => HUMANIZED ANTI-CD45 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 18/632379 [patent_app_country] => US [patent_app_date] => 2024-04-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8202 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 202 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18632379 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19217870 [patent_doc_number] => 20240182574 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-06 [patent_title] => ANTIBODIES TO PROGRAMMED CELL DEATH PROTEIN 1 THAT ARE PD-1 AGONISTS [patent_app_type] => utility [patent_app_number] => 18/423752 [patent_app_country] => US [patent_app_date] => 2024-01-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37663 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18423752 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19172558 [patent_doc_number] => 20240158532 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-16 [patent_title] => ANTIBODY THAT BINDS ERBB-2 AND ERBB-3 [patent_app_type] => utility [patent_app_number] => 18/419527 [patent_app_country] => US [patent_app_date] => 2024-01-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43295 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18419527 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19701525 [patent_doc_number] => 12195534 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-01-14 [patent_title] => Binding molecules [patent_app_type] => utility [patent_app_number] => 18/405977 [patent_app_country] => US [patent_app_date] => 2024-01-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 13 [patent_no_of_words] => 35356 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 107 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18405977 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19521133 [patent_doc_number] => 12122842 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-10-22 [patent_title] => Human CD30-specific binding proteins and uses thereof [patent_app_type] => utility [patent_app_number] => 18/475892 [patent_app_country] => US [patent_app_date] => 2023-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 8386 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 90 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18475892 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18895259 [patent_doc_number] => 20240010744 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-11 [patent_title] => HUMANIZED ANTI-CD45 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 18/464847 [patent_app_country] => US [patent_app_date] => 2023-09-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8418 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18464847 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19083164 [patent_doc_number] => 20240109965 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-04 [patent_title] => IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING T CELL RECEPTOR [patent_app_type] => utility [patent_app_number] => 18/334642 [patent_app_country] => US [patent_app_date] => 2023-06-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30889 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18334642 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19001989 [patent_doc_number] => 20240066060 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-29 [patent_title] => METHODS FOR TREATING INHERITED METABOLIC DISORDERS [patent_app_type] => utility [patent_app_number] => 18/308587 [patent_app_country] => US [patent_app_date] => 2023-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16160 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18308587 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19067213 [patent_doc_number] => 20240101639 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-28 [patent_title] => FC Monomer Polypeptide and Application Thereof [patent_app_type] => utility [patent_app_number] => 18/250568 [patent_app_country] => US [patent_app_date] => 2023-04-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15317 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 250 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18250568 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18552167 [patent_doc_number] => 20230250176 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-10 [patent_title] => PPHARMACEUTICAL FORMULATIONS AND THERAPEUTIC USES OF MULTI-SPECIFIC BINDING PROTEINS THAT BIND EGFR, NKG2D, AND CD16 [patent_app_type] => utility [patent_app_number] => 18/166769 [patent_app_country] => US [patent_app_date] => 2023-02-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 112275 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -490 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18166769 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18657743 [patent_doc_number] => 20230303697 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-28 [patent_title] => Antiaging effect of Intradermal Administration of Immune Checkpoint Inhibitors [patent_app_type] => utility [patent_app_number] => 17/803947 [patent_app_country] => US [patent_app_date] => 2023-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12883 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 170 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17803947 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18405807 [patent_doc_number] => 20230167158 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-01 [patent_title] => PSEUDOTYPED VIRUSES CONFIGURED TO EXPRESS CAR IN T-CELLS [patent_app_type] => utility [patent_app_number] => 18/096167 [patent_app_country] => US [patent_app_date] => 2023-01-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22651 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18096167 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18628276 [patent_doc_number] => 20230287132 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-14 [patent_title] => METHODS OF TREATING OR REDUCING RISK OF TRANSPLANT REJECTION [patent_app_type] => utility [patent_app_number] => 18/152519 [patent_app_country] => US [patent_app_date] => 2023-01-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37911 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18152519 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18434351 [patent_doc_number] => 20230181645 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-15 [patent_title] => METHOD TO IMPROVE CANCER VACCINES [patent_app_type] => utility [patent_app_number] => 18/065320 [patent_app_country] => US [patent_app_date] => 2022-12-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12419 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18065320 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18436066 [patent_doc_number] => 20230183360 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-15 [patent_title] => Use of Amivantamab to Treat Colorectal Cancer [patent_app_type] => utility [patent_app_number] => 18/077318 [patent_app_country] => US [patent_app_date] => 2022-12-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16894 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18077318 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18739657 [patent_doc_number] => 20230348619 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-02 [patent_title] => Combination Of T-Cell Redirecting Multifunctional Antibodies With Immune Checkpoint Modulators And Uses Thereof [patent_app_type] => utility [patent_app_number] => 18/070965 [patent_app_country] => US [patent_app_date] => 2022-11-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36233 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18070965 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18597287 [patent_doc_number] => 20230272082 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-31 [patent_title] => ANTI-VISTA ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/053996 [patent_app_country] => US [patent_app_date] => 2022-11-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35479 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -34 [patent_words_short_claim] => 1777 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18053996 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19793364 [patent_doc_number] => 12234294 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-02-25 [patent_title] => Pharmaceutical composition of a humanized anti-CD40 antibody [patent_app_type] => utility [patent_app_number] => 18/051833 [patent_app_country] => US [patent_app_date] => 2022-11-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 8105 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 74 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18051833 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18336968 [patent_doc_number] => 20230128917 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-27 [patent_title] => GENETICALLY ENGINEERED IMMUNE CELLS HAVING A DISRUPTED CD83 GENE [patent_app_type] => utility [patent_app_number] => 17/931701 [patent_app_country] => US [patent_app_date] => 2022-09-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26594 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17931701 [rel_patent_id] =>[rel_patent_doc_number] =>)